drugset / Trial / NCT06914037
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1
Recruiting
24 enrolled
Tianjin Medical University Cancer Institute and Hospital
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
Timeline
- Start
- 2025-03-31
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CHT101 | Cell therapy | — | — |